IDEAYA Biosciences announces positive data from Phase II trial of cancer treatment

Ideaya Biosciences, a US biotech firm, has released promising interim results from a Phase II trial of IDE397 for treating methylthioadenosine phosphorylase (MTAP) deletion-associated urothelial and non-small cell lung cancers (NSCLC). The study administered a daily 30mg dose of IDE397 to 18 evaluable patients, encompassing urothelial cancer, adenocarcinoma NSCLC, and squamous NSCLC.

Initial findings reveal a 39% overall response rate and a 94% disease control rate, with 78% experiencing tumor shrinkage. According to RECIST 1.1 criteria, one patient achieved complete response, and six showed partial responses among those assessed.

Moreover, the trial reported an 81% molecular response rate in circulating tumor DNA. Initial durability assessment via CT-scan swim lane plots showed 11 patients still on treatment, with five maintaining RECIST 1.1 response.

IDE397 exhibited a favorable safety profile, with no drug-related serious adverse events observed at the 30mg once-daily expansion dose. Ideaya also launched a Phase I trial combining IDE397 with Trodelvy for MTAP-deletion bladder cancer, marking further advancements in its clinical development pipeline.